Detalhe da pesquisa
1.
A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med
; 197(1): 94-103, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28787186
2.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants.
Clin Pharmacol Drug Dev
; 2024 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38523487
3.
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease.
Clin Pharmacol Ther
; 115(3): 565-575, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38115209
4.
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma.
Eur Respir J
; 41(2): 330-8, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22743678
5.
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.
ERJ Open Res
; 9(5)2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37868151
6.
Understanding and working with the concept of denial and its role as a coping strategy.
Nurs Times
; 105(32-33): 22-4, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19736742
7.
Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study.
Adv Ther
; 33(2): 225-51, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26843086
8.
A GP's notes.
Br J Gen Pract
; 62(603): 516, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23265201